- Home
- MESO vs PCT Comparison
MESO vs PCT Comparison
Compare MESO & PCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- PCT
- Stock Information
- Founded
- MESO 2004
- PCT 2015
- Country
- MESO Australia
- PCT United States
- Employees
- MESO N/A
- PCT N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- PCT Environmental Services
- Sector
- MESO Health Care
- PCT Utilities
- Exchange
- MESO Nasdaq
- PCT Nasdaq
- Market Cap
- MESO 2.0B
- PCT 1.8B
- IPO Year
- MESO N/A
- PCT N/A
- Fundamental
- Price
- MESO $18.04
- PCT $9.55
- Analyst Decision
- MESO Buy
- PCT Strong Buy
- Analyst Count
- MESO 4
- PCT 4
- Target Price
- MESO $13.50
- PCT $12.50
- AVG Volume (30 Days)
- MESO 828.2K
- PCT 1.8M
- Earning Date
- MESO 02-28-2025
- PCT 03-05-2025
- Dividend Yield
- MESO N/A
- PCT N/A
- EPS Growth
- MESO N/A
- PCT N/A
- EPS
- MESO N/A
- PCT N/A
- Revenue
- MESO $5,902,000.00
- PCT N/A
- Revenue This Year
- MESO $65.99
- PCT N/A
- Revenue Next Year
- MESO $425.77
- PCT $1,823.98
- P/E Ratio
- MESO N/A
- PCT N/A
- Revenue Growth
- MESO N/A
- PCT N/A
- 52 Week Low
- MESO $1.72
- PCT $3.13
- 52 Week High
- MESO $22.00
- PCT $15.58
- Technical
- Relative Strength Index (RSI)
- MESO 59.20
- PCT 36.45
- Support Level
- MESO $15.92
- PCT $9.31
- Resistance Level
- MESO $17.67
- PCT $10.12
- Average True Range (ATR)
- MESO 1.38
- PCT 0.56
- MACD
- MESO -0.37
- PCT -0.03
- Stochastic Oscillator
- MESO 37.14
- PCT 23.59
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About PCT PureCycle Technologies Inc. Common stock
PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.